Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder

Abstract There are currently five programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors approved for the treatment of locally advanced or metastatic urothelial carcinoma (UC) of the bladder. For platinum-ineligible patients, testing of tumor specimens for PD-L1 expression is require...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Georgi Tosev, Wasilijiang Wahafu, Philipp Reimold, Ivan Damgov, Constantin Schwab, Cem Aksoy, Adam Kaczorowski, Albrecht Stenzinger, Joanne Nyarangi-Dix, Markus Hohenfellner, Stefan Duensing
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e0963328ed3e40d1b1cbaada103b02e7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0963328ed3e40d1b1cbaada103b02e7
record_format	dspace
spelling	oai:doaj.org-article:e0963328ed3e40d1b1cbaada103b02e72021-12-02T15:23:16ZDetection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder10.1038/s41598-021-93754-z2045-2322https://doaj.org/article/e0963328ed3e40d1b1cbaada103b02e72021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93754-zhttps://doaj.org/toc/2045-2322Abstract There are currently five programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors approved for the treatment of locally advanced or metastatic urothelial carcinoma (UC) of the bladder. For platinum-ineligible patients, testing of tumor specimens for PD-L1 expression is required. However, scoring of PD-L1 immunohistochemistry is complex due to different antibodies used, the requirement to score expression in different cellular compartments and intratumoral heterogeneity. It can also be difficult to obtain and test longitudinal tumor samples, which would be desirable to monitor treatment responses and tumor evolution under treatment-induced selective pressure. In the present proof-of concept study, we provide evidence that PD-L1 can be detected in the urine of patients with non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Urine PD-L1 levels were significantly higher in NMIBC and MIBC patients when compared to patients with various non-malignant urological diseases. Further prospective and independent studies are required to assess the value of PD-L1 in the urine as a novel biomarker with potential for the early detection, prediction and therapeutic monitoring of patients with UC of the bladder.Georgi TosevWasilijiang WahafuPhilipp ReimoldIvan DamgovConstantin SchwabCem AksoyAdam KaczorowskiAlbrecht StenzingerJoanne Nyarangi-DixMarkus HohenfellnerStefan DuensingNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Georgi Tosev Wasilijiang Wahafu Philipp Reimold Ivan Damgov Constantin Schwab Cem Aksoy Adam Kaczorowski Albrecht Stenzinger Joanne Nyarangi-Dix Markus Hohenfellner Stefan Duensing Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
description	Abstract There are currently five programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors approved for the treatment of locally advanced or metastatic urothelial carcinoma (UC) of the bladder. For platinum-ineligible patients, testing of tumor specimens for PD-L1 expression is required. However, scoring of PD-L1 immunohistochemistry is complex due to different antibodies used, the requirement to score expression in different cellular compartments and intratumoral heterogeneity. It can also be difficult to obtain and test longitudinal tumor samples, which would be desirable to monitor treatment responses and tumor evolution under treatment-induced selective pressure. In the present proof-of concept study, we provide evidence that PD-L1 can be detected in the urine of patients with non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Urine PD-L1 levels were significantly higher in NMIBC and MIBC patients when compared to patients with various non-malignant urological diseases. Further prospective and independent studies are required to assess the value of PD-L1 in the urine as a novel biomarker with potential for the early detection, prediction and therapeutic monitoring of patients with UC of the bladder.
format	article
author	Georgi Tosev Wasilijiang Wahafu Philipp Reimold Ivan Damgov Constantin Schwab Cem Aksoy Adam Kaczorowski Albrecht Stenzinger Joanne Nyarangi-Dix Markus Hohenfellner Stefan Duensing
author_facet	Georgi Tosev Wasilijiang Wahafu Philipp Reimold Ivan Damgov Constantin Schwab Cem Aksoy Adam Kaczorowski Albrecht Stenzinger Joanne Nyarangi-Dix Markus Hohenfellner Stefan Duensing
author_sort	Georgi Tosev
title	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
title_short	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
title_full	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
title_fullStr	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
title_full_unstemmed	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
title_sort	detection of pd-l1 in the urine of patients with urothelial carcinoma of the bladder
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e0963328ed3e40d1b1cbaada103b02e7
work_keys_str_mv	AT georgitosev detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT wasilijiangwahafu detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT philippreimold detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT ivandamgov detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT constantinschwab detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT cemaksoy detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT adamkaczorowski detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT albrechtstenzinger detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT joannenyarangidix detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT markushohenfellner detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder AT stefanduensing detectionofpdl1intheurineofpatientswithurothelialcarcinomaofthebladder
_version_	1718387297733312512

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder

Ejemplares similares